Evaluation and treatment of hypertension

Primary Care Update for Ob/Gyns

Volumn 7, Issue 1, 2000, Pages 1-6

  Archer, Johanna S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; MINOXIDIL; PRAZOSIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TRIAMTERENE; VALSARTAN; VERAPAMIL;

ARTICLE; CARDIOVASCULAR RISK; DRUG CHOICE; EVALUATION; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LIFESTYLE; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN;

EID: 0033978064     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(99)00032-3     Document Type: Article

References (15)

1. Hall W.D., Ferrario C.M., Moore M.A., et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci. 313:(4):1997;195-209.
2. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). 1997;National Institutes of Health.
3. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
4. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 156:1996;1789-1796.
5. Gueyffier F., Boutitie F., Boissel J.P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med. 126:1997;761-767.
6. National high blood pressure education program working group report on hypertension in diabetes. Hypertension. 23:1994;145-158.
7. rd ed. 1993;W.B. Saunders, Philadelphia (PA).
8. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. Arch Intern Med. 157:1997;657-667.
9. Blair S.N., Goodyear N.N., Gibbons L.W., Cooper K.H. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 252:1984;487-490.
10. Neaton J.D., Grimm R.H., Prineas R.J., et al. Treatment of mild hypertension study final results . JAMA. 270:1993;713-724.
11. Morisky D.E., Levine D.M., Green L.W., Shapiro S., Russell R.P., Smith C.R. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health. 73:1983;153-162.
12. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents a systematic review and meta-analysis . JAMA. 277:1997;739-745.
13. Kaplan N.M., Gifford R.W. Choice of initial therapy for hypertension. JAMA. 275:1996;1577-1580.
14. Cutler J.A. Calcium-channel blockers for hypertension-uncertainty continues. N Engl J Med. 338:1998;679-681.
15. Materson B.J., Reda D.J., Preston R.A., et al. Response to a single anti-hypertensive agent used as monotherapy for hypertension after the failure of the initial drug. Arch Intern Med. 155:1995;1757-1762.